相关实验视频

Updated: Jul 4, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

作为宫癌的第二或第三线治疗方法,tisotumab vedotin的成本效益

Gengwei Huo^1,2,3,4, Wenjie Liu^1,2,3,4, Peng Chen^1,2,3,5

¹Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Journal of gynecologic oncology

|February 8, 2024

概括

与化疗相比,tisotumab vedotin不太可能在治疗复发性或转移性宫癌方面具有成本效益. 这种药物提供了最低额外的质量调整寿命年 (QALYs),但从美国纳税人的角度来看,成本要高得多.

科学领域:

在瘤学瘤学.
卫生经济学卫生经济学
药物经济学药物经济学

背景情况:

再发性或转移性子宫癌存在重大治疗挑战.
化疗是一种标准治疗方法,但正在研究新型疗法.

研究的目的:

评估tisotumab vedotin与治疗复发性或转移性宫癌的化疗之间的成本效益.
从美国付款人的角度评估第二线或第三线治疗的经济价值.

主要方法:

一个三态马尔科夫模型模拟了患者治疗途径.
数据来源于innovaTV 301随机临床试验和文献.
使用了成本和质量调整的寿命年 (QALY) 数据.

主要成果:

提索托马布维多丁产生了0.25个额外的QALY,增加了206,779美元的成本.
增量成本效益比 (ICER) 为每个QALY.88的839,107.88美元.
敏感性分析确定了药物成本和疾病进展是关键因素.

结论:

对于美国纳税人来说,tisotumab vedotin在15万美元/QALY门上是不具有成本效益的.
降低tisotumab vedotin的价格可以提高其经济可行性.
在这种情况下,化疗仍然是一个更具成本效益的选择.

关键词:

宫癌宫癌是什么成本效益分析成本效益分析质量调整的生命年数这就是Tisotumab Vedotin.

更多相关视频

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.